by Prochlorperazine maleate is a first-generation phenothiazine-class antipsychotic and antiemetic drug used for treating severe nausea and vomiting. It works by blocking dopamine receptors in the brain’s chemoreceptor trigger zone, which controls vomiting. The drug is commonly administered orally, rectally, intramuscularly, or intravenously and is used to prevent and treat nausea and vomiting associated with chemotherapy, surgery, and post-operative care. It is also used for nausea and vomiting caused by gastrointestinal disorders such as migraines.
The global Prochlorperazine Maleate Market is estimated to be valued at Us$ 1.46 Bn in 2023 and is expected to exhibit a CAGR Of 3.5% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Rising prevalence of nausea and vomiting disorders and increasing number of surgeries performed globally are expected to be the key drivers for the growth of the prochlorperazine maleate market over the forecast period. According to the National Institute of Diabetes and Digestive and Kidney Diseases, around one in every 10 Americans experience nausea and vomiting. The Center for Disease Control and Prevention reported over 51 million surgeries performed in the United States in 2020, exposing a large patient pool to post-operative nausea and vomiting daily. A growing geriatric population also susceptible to gastrointestinal disorders like IBS would further boost the market demand. Moreover, prochlorperazine’s effectiveness, easy availability as generic drug, and affordability make it a preferred initial treatment option over newer antiemetics, thereby propelling the market growth. However, adverse effects and availability of alternative medicines may hamper the growth of prochlorperazine maleate market.
Segment Analysis
The global prochlorperazine maleate market can be segmented based on dosage form, application, distribution channel, and region. Under dosage form, tablets dominate the market as they are more convenient to consume. Tablets accounted for over 35% share of the global market in 2023 due to ease of administration. In terms of application, nausea and vomiting application led the market in 2023 with over 45% share as prochlorperazine maleate is widely used for treating nausea and vomiting associated with certain medical conditions and post-surgery. Hospitals distribution channel dominated with over 30% share as it is a popular setting for administering prochlorperazine maleate injection and addressing nausea & vomiting in in-patients.
PEST Analysis
Political: Changes in healthcare regulations across regions impact availability and pricing of prochlorperazine maleate drugs. Economic: Affordability of products influences market growth. Social: Increasing prevalence of nausea & vomiting disorders drives market growth. Technological: Development of novel drug delivery systems and pharmaceutical formulations will boost market opportunities.
Key Takeaways
The Global Prochlorperazine Maleate Market Demand was valued at US$ 1.46 Bn in 2023 and is projected to reach US$ 2.12 Bn by 2030, growing at a CAGR of 3.5% during the forecast period. Regional analysis: North America held the largest share of over 35% in the global market in 2023 due to advanced healthcare infrastructure and high treatment rates for nausea and vomiting.
Key players:
Key players operating in the prochlorperazine maleate market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Limited.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
